Skip to search formSkip to main contentSkip to account menu

bleomycin/cytarabine/methotrexate/vincristine

Known as: ARA-C/BLEO/MTX/VCR, CytaBOM 
National Institutes of Health

Related topics

Related topics

4 relations
BleomycinCytarabineMethotrexateVincristine

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2010
2010
In vitro and in vivo study on the antioxidant activity of dexrazoxane.
2000
2000
Clinical relevance of the lung resistance protein in diffuse large B-cell lymphomas.
Drug resistance of non-Hodgkin's lymphomas may involve mechanisms of the multidrug resistance phenotype including the lung… 
Highly Cited
1999
Highly Cited
1999
The International Prognostic Index can be used as a guide to treatment decisions regarding patients with human immunodeficiency virus—related systemic non‐Hodgkin lymphoma
The International Prognostic Index (IPI) effectively separates aggressive lymphomas into four groups with significantly different… 
1999
1999
A phase II trial of 200% ProMACE-CytaBOM in patients with previously untreated aggressive lymphomas: analysis of response, toxicity, and dose intensity.
We showed in a phase I trial that the maximum tolerated dose of the ProMACE-CytaBOM regimen in patients with aggressive lymphoma… 
1998
1998
Efficacy of two different ProMACE-CytaBOM derived regimens in advanced aggressive non-Hodgkin's lymphoma. Final report of a multicenter trial conducted by GISL.
BACKGROUND AND OBJECTIVE To compare the efficacy of ProME(Epidoxorubicin)CE-CytaBOM (PE-C) and ProMI(Idarubicin)CE-CytaBOM (PI-C… 
Highly Cited
1996
Highly Cited
1996
Compound heterozygosity for unstable hemoglobin Genova and beta(o)-thalassemia associated with early onset of thalassemia major syndrome.
We described the case of an infant with compound heterozygozity for a b0-thalassemic mutation and Hemoglobin (Hb) Genova, an… 
1996
1996
CHOP vs. ProMACE‐CytaBOM in the treatment of aggressive non‐Hodgkin's lymphomas: long‐term results of a multicenter randomized trial
Abstract:  From May 1985 to May 1989, 175 patients with previously untreated aggressive non‐Hodgkin's lymphoma were randomized to… 
1996
1996
Phase I trial of dose escalation with growth factor support in patients with previously untreated diffuse aggressive lymphomas: determination of the maximum-tolerated dose of ProMACE-CytaBOM.
PURPOSE The aim of this study was to determine the maximum-tolerated dose (MTD) of cyclophosphamide, doxorubicin, etoposide… 
1988
1988
Leukemia of non-T lineage natural killer cells
An unusual case of an aggressive leukemia of natural killer (NK) cells occurred in a 65-year-old male. Clinical characteristics… 
1988
1988
Leukemia of non-T lineage natural killer cells.
An unusual case of an aggressive leukemia of natural killer (NK) cells occurred in a 65-year-old male. Clinical characteristics… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)